A 38-year-old woman's tumor had wrapped itself around a major artery deep in her abdomen, the kind of growth that surgeons normally cannot cut away without risking catastrophic damage to the organs it was feeding on. So a Cleveland Clinic surgical team took an extreme approach: they removed her entire small intestine, along with the tumor and part of her pancreas, operated on the tumor outside her body, and then put the intestine back.
Cleveland Clinic announced this week that it is the first health system in Ohio to report performing the procedure, known as ex vivo intestinal autotransplantation, according to a statement from Cleveland Clinic. The hospital said the operation is performed at only a small number of centers worldwide, placing the Cleveland team in rare company among surgeons willing and able to attempt it.
A Tumor Too Dangerous to Cut Away Conventionally
The patient's tumor surrounded her superior mesenteric artery, a vessel that supplies blood to much of the small intestine, according to the hospital's account. Doctors determined it could not be safely removed using conventional surgery, since cutting near or through that artery risked cutting off blood supply to the bowel itself.
Instead, the surgical team removed the tumor, the pancreatic head and the entire small intestine as one unit, treating the mass outside the patient's body before reconstructing and reimplanting the intestine using vascular and gastrointestinal techniques, per the hospital's report. Masato Fujiki, M.D., surgical director of Cleveland Clinic's Intestinal Transplant Program, led a multidisciplinary team that included hepatobiliary and pancreatic surgeon Robert Naples, D.O., in completing the procedure earlier this year, the hospital said.
Patient Back Home and Recovering
Following the surgery and additional procedures, the woman has returned home and is recovering well, Cleveland Clinic reported. As FOX 8 News also reported, the case marked the hospital's first of its kind performed on a patient of this profile.
Why So Few Hospitals Attempt It
Published research helps explain why this surgery remains so uncommon. A study in the journal Annals of Surgery described the technique, known as IATx, as an option for tumors arising from the pancreas, duodenum, mesentery or retroperitoneum when they involve the superior mesenteric artery, and noted it is a novel approach rather than a routine one, per the account from sciencedirect.com.
That same body of research shows the stakes involved. A 2020 study tracking 15 patients who underwent the procedure found that ten developed a combined 23 postoperative complications, and one patient lost the bowel autograft entirely due to arterial thrombosis, according to the sciencedirect.com report. Still, at a median follow-up of nearly 30 months, 11 of those patients remained alive with well-functioning bowel grafts, the same study found.
More recent data points toward cautious optimism. An international multicenter study that analyzed 35 patients treated across five institutions found complete tumor removal was achieved in 85.7% of cases, with no deaths within 90 days of surgery, according to findings published in the Annals of Surgery. Researchers concluded the technique can be performed with low perioperative mortality and acceptable outcomes in carefully selected patients whose tumors would otherwise be considered unresectable.
A Short List of Centers Nationally
Cleveland Clinic is not alone in offering the procedure, though the list of hospitals equipped to do so remains short. Surgeons at NewYork-Presbyterian Hospital and Columbia University Irving Medical Center have established their own method of ex vivo tumor resection for growths involving blood vessels that supply major abdominal organs, according to ColumbiaDoctors. That approach can involve removing the intestine, liver or other abdominal organs as needed to access a tumor before reimplanting the patient's own organs, and the two institutions are counted among the few U.S. transplant centers with the expertise to offer it.
One advantage of the approach, per ColumbiaDoctors, is that patients who undergo autotransplantation need no immunosuppressant medications afterward, since the reimplanted organs are their own rather than a donor's. A separate review published on pmc.ncbi.nlm.nih.gov cautioned that given the procedural complexity, the surgery should be performed exclusively at expert centers, and that further long-term follow-up studies are still needed to validate outcomes.
